Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.63% 79.50 196,441 16:08:14
Bid Price Offer Price High Price Low Price Open Price
79.00 80.00 79.50 79.00 79.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.68 -10.87 -6.56 137
Last Trade Time Trade Type Trade Size Trade Price Currency
16:30:57 O 35,000 80.00 GBX

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
16/10/201911:28ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY1,639
28/2/201912:22ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET11,356
28/8/201812:29ANGLE plc (AGL) One to Watch -
02/7/201812:06Still time to look at Angle (AGL)-
14/5/201809:44ANGLE (AGL) Strategic Move-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-17 17:30:5780.0035,00028,000.00O
2019-10-17 15:30:4880.0029,44423,555.20O
2019-10-17 14:30:4179.564,0003,182.40O
2019-10-17 14:03:5978.756,7465,312.48O
2019-10-17 13:01:4480.0050,00040,000.00O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 79p.
Angle Plc has a 4 week average price of 75.80p and a 12 week average price of 66.50p.
The 1 year high share price is 85.50p while the 1 year low share price is currently 38p.
There are currently 172,754,816 shares in issue and the average daily traded volume is 106,556 shares. The market capitalisation of Angle Plc is £137,340,078.72.
sicilian_kan: The option agreement expires in just 20 months. Would be interesting to know the terms - how much AGL need to pay to exercise the option agreement. The extent of the payment required could have both a positive and a negative impact on the share price, depending on the amount. As ever from AGL, we only get part of the story. A shame because the news is actually good.
sicilian_kan: The problem here is the market cap, which is already very high. There are 172,754,816 shares in issue and a further 20,555,806 options in place. So the market cap at today’s price is already £136m. Fully diluted it is £153m. That is a lot for a company with a poor sales track record (missing all their initial targets) and without FDA approval. Yes FDA approval would help the share price significantly, but if the FDA in examining the data wanted a further trial, shareholders could have 50% of their investment wiped out overnight. So there are risks and at the moment Newland has not released the data on the MBC trial just the fact of the endpoint being met (and the need for further analytical studies). Without that data or the reasons for the analytical studies or confirmation of their success, shareholders can not properly assess the likely strength of any FDA application and there remains, as bones sets out, significant risk in the FDA process re timing and requirements. Would not be surprised if the share price will pull back 5-12p or so as the (justified) excitement fades over the prostate news and media reporting.
alloa2003: I think the AGL share price is starting to reflect the potential value based on the risk that it may or may not be realised. For example if the potential value was £2 a share (based on profit, pe ratio, etc) and the chance of being successful was deemed 80% then you would expect the price to be much closer to £2. It is a form of arbitration with the share price reflecting the risk/reward factor compared to potential "fair value".
sicilian_kan: If the MBC trial is not, on the existing data (however confident one is) a nailed on certainty, surely the next questions are: 1) What is the best estimate probability of commercial data appearing in the MBC trial? 2) What share price spectrum might arise if the trial demonstrates commercial data? 3) What share price spectrum might arise if the trial does not demonstrate commercial data? Then an investment strategy can be formulated. There is far too little analysis of the actual MBC data that is available. There is also far too little analysis on here of the chance of success and on the share price gains and falls that might occur upon the MBC trial data being released.
alloa2003: There has been a sea change in the AGL share price of late, no highs then sharp reversals on announcements and no drifting on a lack of news. There is strong underlying demand for the shares which leads me to believe things are afoot behind the scenes.
sicilian_kan: At 70p, AGL's fully diluted market cap is £126m. 143,486,522 shares in issue, plus 20,555,806 options etc. = 164,042,328 shares fully diluted. This might see a 75p top before news, but quite frankly, the current share price is way overvalued given the risk involved, the laborious process involved (see youtube video) and the likely revenues from MBC. Given the hype around AGL, I think on good news 100-150p could be hit. On bad MBC results, we are looking at 10p-35p depending on how bad the results are. Results could also be mixed. So short term upside of 50-100%, short term downside potential of 50-80%. Chance of success, say 80-85%? I bear in mind that the ovarian trial was disappointing relative to the earlier study results. With significant downside possibility, I would expect a risk reward ratio of at least 3:1 to make this attractive. Fair price circa 50-55p? For those in at that level, it is definitely worth a hold, but I do not see buying in at the current share price as being in any way attractive.
semper vigilans: As usual a decent bit of research from a large, highly reputable organisation working in the right field, is not really recognised by the market. Whatever one thinks of false starts earlier, at some stage the build up of published, independent research must give the AGL share price a decent, upward shove?
alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support.
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
Angle share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 00:31:19